The Food and Drug Administration (FDA) approved Prezista – 800 mg (Darunavir) for treatment of HIV-1 infection in treatment-experienced and treatment-naïve adults without known darunavir-resistance. Prezista – 800 is once-daily oral medication that is to be prescribed with Ritonavir or other anti-HIV drugs that should be taken after meals. Prezista 800 is developed by Janssen Therapeutics of Janssen Products.
The new drug is an alternative for twice daily (400 mg) Prezista tablets, and it can take as once daily with other prescribed medications. The pharmacists and the physicians will be educated about the new transitional doses by product inserts. Prezista is a protease inhibitor, and it is classified as a prescription medicine.
According to Bryan Baugh, the single dose of Prezista 800 mg will allow the patients consumers to take a once-daily dose with convenience. The development of Prezista 800 mg is the best example of Janssen’s commitment towards well-being of HIV patients, he said.
Prezista is expected to be marketed within a month in the global market. However, Janssen will continue marketing of Prezista 400 mg tablets. Prezista 800 mg tablets will be one of the Janssen Therapeutics Patient Savings Program.
Unichem Laboratories Ltd.